



## General description

Nilotinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for chronic myeloid leukaemia

|                    |   |
|--------------------|---|
| INN                | Nilotinib   |
| ATC codes          | L01EA03   |
| Medicine type      | Chemical agent  |
| EML status history | First added in 2017 (TRS 1006) for <b>Chronic myeloid leukaemia, not elsewhere classified</b>               |
| Wikipedia          | <a href="#">Nilotinib</a>  |
| DrugBank           | <a href="#">Nilotinib</a>  |

## Recommendations

### Section Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

### Indications

Chronic myeloid leukaemia, not elsewhere classified

